Source - SMW
Oxford BioDynamics said it had entered into a collaboration with Holos Life Sciences to develop non-invasive epigenetic biomarkers associated with sports-related concussions.

Under the terms of the agreement, Holos would supply the participants' blood samples, with Oxford BioDynamics providing its EpiSwitch platform for the development, evaluation, and validation of epigenetic biomarkers.

'Based on our previous studies and stratification results, we believe that we can make an important contribution to the analysis of sport-related concussions, help improve the rehabilitation protocols and directly assist individual athletes and their teams in their training planning,' Oxford BioDynamics chief executive Christian Hoyer Millar said.

At 9:45am: (LON:OBD) Oxford Biodynamics Plc share price was +1.5p at 192p